EKSO Trial: Powered Exoskeleton for Ambulation in Subjects With SCI

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Rehabilitation Institute of Chicago
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Arun Jayaraman, Rehabilitation Institute of Chicago
ClinicalTrials.gov Identifier:
NCT01701388
First received: August 20, 2012
Last updated: July 7, 2014
Last verified: July 2014
  Purpose

This study seeks to test the safety and efficacy of the Esko device in SCI population and in populations with similar neurological weakness to the SCI population. The device can currently stand from a seated position, walk, and turn and sit down. Our hypothesis are as follows:

  • Hypothesis 1: We hypothesize that the Ekso subject will significantly improve balance while wearing the device as noted by subject's ability to safely achieve standing balance for 30 sec without loss of balance.
  • Hypothesis 2: We hypothesize that the Ekso subject will display improved ability to safely ambulate 10 meters to be assessed using the 10 meter walk test.
  • Hypothesis 3: We hypothesize that the Ekso subject will display improved weight shift in both static and dynamic activities as determined by a trained physical therapist.
  • Hypothesis 4: We hypothesize that the Ekso subject will verbalize improved success with training of the device as noted by subjective questionnaires that will be assessed following each training session.

Condition Intervention Phase
Spinal Cord Injuries or Similar Neurological Weakness.
Device: Ekso exoskeleton
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Investigational Study of the Ekso Powered Exoskeleton for Ambulation in Individuals With Spinal Cord Injury (or Similar Neurological Weakness)

Resource links provided by NLM:


Further study details as provided by Rehabilitation Institute of Chicago:

Primary Outcome Measures:
  • Change in 6 Minute Walk Test from baseline in distance, RPE and oxygen uptake [ Time Frame: Testing Day 1 - 3 and follow up testing Week 6 and Week 12. ] [ Designated as safety issue: No ]
    The goal is to cover as much ground as possible over 6 minutes, the distance is measured with a measuring wheel. The instructions are "Walk continuously if possible, but do not be concerned if you need to slow down or stop to rest." At the end of 6 minutes the participant is asked to rate their exertion level on a Borg Scale of 6 - 20 points. The VO2 MAX data is collected during the test every 10 seconds

  • change in 10 meter walk test from baseline in gait speed [ Time Frame: Testing Day 1 - 3 and follow up testing Week 6 and Week 12 ] [ Designated as safety issue: No ]
    Measure the time in second for and individual to walk 10 meters. The test is performed using a "flying start," patient walks 10 meters (33 ft) and the time is measured when the leading foot crosses the start line and the finish line. The instructions are: " Please walk this distance as fast as you safely can when I say go."


Secondary Outcome Measures:
  • Ratio of number of steps/walking time [ Time Frame: Testing Day 1 - 3 and follow up testing Week 6 and Week 12. ] [ Designated as safety issue: No ]
    The data will be collected from the Ekso statistics mode [data provided by the machine]

  • 2 Minute Walk Test [ Time Frame: Testing Day 1 and follow up testing Week 6 and Week 12 ] [ Designated as safety issue: No ]
    Individual walks for 2 minutes and the distance is measured, start timing when the individual is instructed to "Go,"stop timing at 2 minutes, assistive devices can be used and documented from test to test, if physical assistance and/or tethering is required it will be recorded as well. The test should be performed at the fastest safest speed possible.

  • Walk time to stand time ratio on a particular assistive device [ Time Frame: Testing Day 1 and follow up testing Week 6 and Week 12 ] [ Designated as safety issue: No ]
    The data will be collected from the statistics section of the Ekso. As patients progress from a rolling walker assistive device to the forearm crutches the ratio will be collected and compared to the initial and then final sessions with that particular device.


Other Outcome Measures:
  • Psychosocial Impact of Assistive Device Scale (PIADS) [ Time Frame: Day 1- 3 after the first trial of the Ekso, follow up testing on Week 6 and Week 12 ] [ Designated as safety issue: No ]

    The PIADS is a 26-item, self-report questionnaire designed to assess the effects of an assistive device on functional independence, well-being, and quality of life.

    The PIADS can be used to assess the impact of any assistive device (AD), prosthesis or medical procedure. It can be used to evaluate the impact of ADs over time and to match the devices with consumers. With its excellent psychometric properties, the PIADS fills a missing link in the assessment of ADs as well as in the examination of their acceptance and abandonment.



Estimated Enrollment: 40
Study Start Date: May 2012
Estimated Study Completion Date: April 2017
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ekso Safety and Efficacy
Observational study on the first time use of a robotic exoskeleton.
Device: Ekso exoskeleton
The participants will receive 1 - 40 training sessions. The sessions will be 1 hour of device use including balance training, gait training and sit to and from stand training with rolling walker and/ or forearm crutches.
Other Name: Ekso by Eksobionics

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Participants must:

  • have a spinal cord injury SCI between C7-S1.
  • be between 18-65 years of age.
  • be able to physically fit into the exoskeletal device.
  • be able to tolerate upright standing for a minimum of 30 minutes.
  • have joint range of motion within normal functional limits for ambulation.
  • have sufficient upper body strength to balance themselves using the walker while wearing the exoskeleton.
  • have a different neurological weakness than SCI but fit the other inclusion criteria above

Exclusion Criteria:

  • Height below 62 inches or above 74 inches
  • Weight above 220 lbs.
  • Joint contractures of any extremity that limits normal ROM during ambulation with assistive devices.
  • Any medical issue that precludes full weight bearing and ambulation (e.g. orthopedic injuries, pain, severe spasticity)
  • Skin issues that would prevent wearing the device.
  • Cognitive and/or communicative disability (e.g. due to brain injury). Patients must be able to follow directions well and demonstrate learning capability.
  • Significant Osteoporosis: Osteoporosis will be graded based on the T score that indicates a person's bone mineral content and is graded as follows: (14)

T +1: Normal bone density:

  • T -1 to -2.5: Low bone density of osteopenia
  • T -2.5 to -3.0: osteoporosis
  • T <-3.0: Severe osteoporosis
  • If the patient has severe osteoporosis and a T score of <-3, participation in the study will be considered based upon their physicians recommendation and overall evaluation of the patient.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01701388

Contacts
Contact: Arun Jayaraman, PhD 312-238-6875 ajayaraman@ric.org
Contact: Lori McGee Koch, BS 312-238-2091 lmcgee@ric.org

Locations
United States, Illinois
Rehabilitation Institute of Chicago Recruiting
Chicago, Illinois, United States, 60611
Contact: Lori McGee Koch, BS    312-238-2091    lmcgee@ric.org   
Sponsors and Collaborators
Rehabilitation Institute of Chicago
Investigators
Principal Investigator: Arun Jayaraman, PhD RIC/Northwestern
  More Information

No publications provided

Responsible Party: Arun Jayaraman, Research Scientist, Rehabilitation Institute of Chicago
ClinicalTrials.gov Identifier: NCT01701388     History of Changes
Other Study ID Numbers: NU59727
Study First Received: August 20, 2012
Last Updated: July 7, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Rehabilitation Institute of Chicago:
Ekso
Exoskeleton
Spinal Cord Injury
Motor Complete Incomplete

Additional relevant MeSH terms:
Asthenia
Spinal Cord Injuries
Wounds and Injuries
Signs and Symptoms
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System

ClinicalTrials.gov processed this record on July 20, 2014